After H.C. Wainwright and Evercore ISI gave Aeglea Biotherapeutics (NASDAQ: AGLE) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Chad Messer reiterated a Buy rating on Aeglea Biotherapeutics today and set a price target of $14.00. The company’s shares closed last Monday at $8.24.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.4% and a 44.6% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aerpio Pharmaceuticals, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Aeglea Biotherapeutics is a Strong Buy with an average price target of $19.00.
Based on Aeglea Biotherapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.57 million. In comparison, last year the company had a GAAP net loss of $11.92 million.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGLE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.